

## Phorbasterones A–D, Cytotoxic *Nor*-Ring A Steroids from the Sponge *Phorbas amaranthus*

Makoto N. Masuno,<sup>†</sup> Joseph R. Pawlik,<sup>‡</sup> and Tadeusz F. Molinski\*<sup>†</sup>

Department of Chemistry, University of California, Davis, California 95616, and Biological Sciences and Center for Marine Science Research, University of North Carolina at Wilmington, North Carolina 28403-3297

Received October 17, 2003

The sponge *Phorbas amaranthus* from Florida contains the new ring A-contracted steroids, phorbasterones A–D, and the known anthosterones A and B. The structures of phorbasterones A–D were determined by interpretation of their spectroscopic data. Phorbasterones show moderate cytotoxicity against HCT-116 tumor cells.

In a systematic survey of Caribbean sponges, Pawlik and co-workers found that extracts of the bright-red sponge *Phorbas amaranthus* deterred feeding by the bluehead wrasse *Thalassoma bifasciatum*.<sup>1</sup> The measured nutrient content of *P. amaranthus* was significant, but the tissue was exceptionally fragile (tensile strength) with no obvious physical defenses.<sup>2</sup> Therefore, the deterrent properties of the sponge are likely attributed to an undescribed “chemical defense”. In our search for the antifeedant principles of *P. amaranthus* we isolated the known oxidized steroids anthosterones A (**1**) and B (**2**) and four new congeners, phorbasterones A–D (**3–6**). Steroids **1** and **2**, with contracted cyclopentane A-rings, were first described by Anderson, Clardy, and co-workers in 1988.<sup>3</sup> Phorbasterones comprise a family of homologues that differ from **1** and **2** by side-chain (C20–29) alkyl branching, isomerism, or oxidation level. In this report, we describe the isolation and structure elucidation of **3–6**. Metabolites from the genus *Phorbas* are rare. The only other natural products described from this genus are the alkaloids phorbazoles from a Red Sea species (*Phorbas* aff. *clathrata*),<sup>4</sup> the potent cytotoxic phorboxazoles A and B from a Western Australian *Phorbas* species,<sup>5,6</sup> the monocyclic diterpenoids phorbasins A and B from an Australian species,<sup>7</sup> and the gagunins, which are highly oxygenated verrucosane diterpenes.<sup>8</sup> Phorbasterones **3–6** were found to be cytotoxic to HCT-116 cells (IC<sub>50</sub> 1–3 μg/mL).

Samples of *P. amaranthus* collected by hand (scuba) at Dry Rock, Key Largo, Florida, were immediately frozen and kept at –20 °C until needed. The CHCl<sub>3</sub>-soluble fraction, obtained after preliminary methanol extraction of the sponge, was purified by sequential column chromatography (silica, EtOAc–CH<sub>2</sub>Cl<sub>2</sub>, MeOH–CH<sub>2</sub>Cl<sub>2</sub> gradient), Sephadex LH20 chromatography (hexane–CH<sub>2</sub>Cl<sub>2</sub>, 1:3), and reversed-phase HPLC (C<sub>8</sub>, Microsorb, MeOH–H<sub>2</sub>O followed by C<sub>18</sub>, Microsorb, CH<sub>3</sub>CN–H<sub>2</sub>O) to afford anthosterones A and B (**1** and **2**) and phorbasterones A–D (**3–6**). Compounds **1** and **2** were identified by comparison of <sup>1</sup>H and <sup>13</sup>C NMR data with those of reported values,<sup>3</sup> while the structures of **3–6** were derived as follows.

Anthosterones **1** and **2** and the phorbasterones share a characteristic ring A-contracted steroid nucleus of general structure **7** (Figure 1). The core <sup>13</sup>C NMR resonances (C1 to C19) were virtually identical for each compound (Table




Figure 1.

1). Key <sup>1</sup>H NMR signals, including the isolated geminal signals H<sub>2</sub>-1 (δ 2.08, d, *J* = 13.3 Hz, 1H; 2.16, d, *J* = 13.3 Hz, 1H)<sup>3</sup> and H-6 (δ 6.72, t, *J* = 3.3 Hz, 1H), assigned to a highly polarized α,β-unsaturated cyclopentenone and the C18 and C19 angular methyl groups (δ 0.73, s, 3H; 1.21, s, 3H), confirmed the presence of an exocyclic double bond conjugated to the cyclopentanone ring. The structural differences between **1**, **2**, and the new compounds **3–6** could be attributed solely to differences in the side chains and assigned by examination of the <sup>1</sup>H and <sup>13</sup>C NMR spectra.

Compound **3**, C<sub>29</sub>H<sub>44</sub>O<sub>4</sub>, was isomeric with **2** by a desorption electron impact mass spectrum (DEI, *m/z* 456.3247 [M<sup>+</sup>]). The <sup>1</sup>H NMR spectrum of **3** (CDCl<sub>3</sub>) revealed signals due to a 1,2-disubstituted vinyl group (δ 5.15, m, 2H, H-22, H-23) and four methyl groups (δ 1.00, d, *J* = 6.6 Hz, 3H; 0.89, d, *J* = 6.9 Hz, 3H; 0.82, d, *J* = 6.9 Hz, 3H; 0.80, d, *J* = 6.6 Hz, 3H). Comparison of the <sup>13</sup>C NMR signals of **3** C20–C28 showed an almost perfect match for (*E*)-22-

\* To whom correspondence should be addressed. Tel: 530 752 6358. Fax: 530 752 8995. E-mail: tfmolinski@ucdavis.edu.

<sup>†</sup> University of California, Davis.

<sup>‡</sup> University of North Carolina at Wilmington.

**Table 1.** Selected  $^{13}\text{C}$  NMR Chemical Shifts of **2**–**6** ( $\delta$ ,  $\text{CDCl}_3$ , 100 MHz)

#	<b>2</b> <sup>a</sup>	<b>3</b> <sup>b</sup>	<b>4</b> <sup>c</sup>	<b>5a</b> <sup>d,h</sup>	<b>5b</b> <sup>e,h</sup>	<b>6a</b> <sup>g,h</sup>	<b>6b</b> <sup>f,h</sup>
2	79.9	79.9	79.9	79.9	79.9	79.9	79.9
3	173.4	173.4	173.4	173.4	173.4	173.4	173.4
4	200.9	200.9	200.9	200.9	200.9	200.9	200.9
5	145.1	145.1	145.1	145.1	145.1	145.1	145.1
6	136.3	136.3	136.3	136.3	136.3	136.3	136.3
20	35.7	40.2 (-0.1)	35.7 (0.0)	40.4 (-0.1)	40.4 (0.0)	36.1 (0.0)	36.2 (0.0)
21	21.9	21.0 (0.0)	18.7 (0.0)	21.1 (0.0)	20.9 (0.0)	18.8 (0.0)	18.8 (0.0)
22	31.0	135.8 (-0.2)	36.1 (0.0)	138.1 (-0.3)	138.0 (-0.2)	33.9 (0.0)	33.9 (0.0)
23	34.6	132.1 (+0.2)	23.8 (0.0)	129.5 (+0.2)	129.5 (+0.2)	26.1 (0.0)	26.4 (0.0)
24	156.8	43.1 (0.0)	39.5 (0.0)	51.2 (0.0)	51.2 (0.0)	45.8 (0.0)	46.0 (0.0)
25	33.8	33.2 (0.0)	28.0 (0.0)	31.9 (0.0)	31.8 (0.0)	29.1 (0.0)	28.9 (0.0)
26	21.9	19.6 <sup>i</sup> (0.0)	22.5 <sup>i</sup> (0.0)	19.0 <sup>i</sup> (0.0)	18.9 <sup>i</sup> (0.0)	19.8 (-0.1)	19.6 (0.0)
27	21.8	20.2 <sup>i</sup> (0.0)	22.8 <sup>i</sup> (0.0)	21.3 <sup>i</sup> (0.0)	21.2 <sup>i</sup> (0.0)	19.0 <sup>i</sup> (0.0)	19.0 <sup>i</sup> (0.0)
28	106.0	18.0 (0.0)		25.4 <sup>i</sup> (0.0)	25.4 <sup>i</sup> (0.0)	23.0 <sup>i</sup> (-0.1)	23.0 <sup>i</sup> (0.0)
29				12.2 (0.0)	12.4 (0.0)	12.3 (0.0)	12.3 (0.0)
MeO	53.4	53.4	53.4	53.4	53.4	53.4	53.4

<sup>a</sup> The numbering for anthosterone B (ref 1) is changed here to be consistent with that for **3**–**6**. Differences in  $\delta$  ( $\Delta\delta$ ) for side-chain resonances (in parentheses) were computed with respect to the following reference compounds. <sup>b</sup> 22-Dehydrocampesterol. <sup>c</sup> 5 $\alpha$ -Cholestan-3-one. <sup>d</sup> Stigmasterol. <sup>e</sup> Poriferasterol. <sup>f</sup> Clionasterol. <sup>g</sup> Sitosterol as follows: [ $\delta_{\text{phorbasterone}} - \delta_{\text{standard sterol}}$ ]. <sup>h</sup> Isolated as a 1:1 mixture. <sup>i</sup> Interchangeable.

dehydrocampesterol,<sup>9,10</sup> which confirms the double-bond location (C22–C23) and configuration in **3**.

Phorbasterone B (**4**),  $\text{C}_{28}\text{H}_{44}\text{O}_4$ , is a lower homologue of **3** (DEI,  $m/z$  444.3240 [ $\text{M}^+$ ]) that contains one less double bond than **1**, as evidenced by lack of side-chain vinyl signals in the  $^1\text{H}$  NMR spectrum of **4** ( $\text{CDCl}_3$ ). Comparison of side-chain  $^{13}\text{C}$  NMR signals, particularly of C20–C27, and the  $^1\text{H}$  NMR methyl signals ( $\delta$  0.93, d,  $J = 6.6$  Hz, 3H; 0.87, d,  $J = 6.6$  Hz, 3H; 0.86, d,  $J = 6.6$  Hz, 3H) matched the signals of a 5 $\alpha$ -cholestan-3-one.<sup>10,11</sup> Thus, phorbasterone B (**4**) is 22,23-dihydroanthosterone A.

Using reversed-phase HPLC under varying conditions we effected a separation of phorbasterones C (**5**) and D (**6**), each as a mixture of epimers. Accurate mass measurement of **5** (DEI  $m/z$  470.3382 [ $\text{M}^+$ ]) revealed a formula  $\text{C}_{30}\text{H}_{46}\text{O}_4$  that corresponds to an ethyl-branched homologue of **3**, while the formula of **6**,  $\text{C}_{30}\text{H}_{48}\text{O}_4$  (DEI,  $m/z$  472.3552 [ $\text{M}^+$ ]), is the 22,23-dihydro derivative of **5**. These structural differences between **5** and **6** were fully supported by an analysis similar to that described for **3** and **4**; however, an observed doubling of side-chain signals in the  $^{13}\text{C}$  NMR spectra suggested that **5** and **6** were each an inseparable 1:1 epimeric mixture, most likely at C-24, from biosynthetic precedents (*cf.* sitosterol and clionasterol, *vide infra*). Consequently, phorbasterones C and D were each characterized as a 1:1 epimeric mixture at C-24 (epimers are indicated by suffixes **a** and **b**).

Analysis of the  $^1\text{H}$  NMR spectrum of **5** ( $\text{CDCl}_3$ ) supported a disubstituted *E*-double bond at C22,23 ( $\delta$  5.14, ddd,  $J = 2.8, 8.4, 15.2$  Hz, 1H; 5.01, ddd,  $J = 2.0, 8.4, 15.2$  Hz, 1H). Inspection of the DQF-COSY spectrum showed four methyl groups ( $\delta$  1.02, d,  $J = 6.4$  Hz, 3H; 0.84–0.76, overlapped, m, 9H), one of which was part of an ethyl group, as suggested by a cross-peak between an overlapped  $\text{CH}_3$  signal and a  $\text{CH}_2$  signal at  $\delta$  1.65 (m). However, the  $^1\text{H}$

NMR signals were not sufficiently dispersed to allow accurate  $^1\text{H}$  NMR chemical shift or coupling constant measurements. Instead, examination of the  $^{13}\text{C}$  NMR spectra of **5**, including the DEPT spectra, revealed the expected additional  $\text{CH}_2$  ( $\delta$  25.4, t, C28) and exceptionally high-field  $\text{CH}_3$  signal ( $\delta$  12.2, q, C29) of the ethyl group and allowed complete assignment of the structures of **5** and **6**, including stereochemistry, as follows.

The stereochemical assignment of the C-24 configuration followed from careful pairwise comparison and least-difference analysis of  $^{13}\text{C}$  NMR chemical shifts in **5a** and **5b** with those of the assigned side-chain signals of the known C-24 epimers, stigmasterol<sup>10,12</sup> and poriferasterol<sup>10,13</sup> (Table 1). Since *diastereomeric* differences observed in the side-chain  $^{13}\text{C}$  NMR signals are most likely influenced by the nearest stereogenic center, C-20 (which is invariably 20*R* in natural sterols), the pairwise analysis of  $^{13}\text{C}$  NMR chemical shifts allows assignment of *absolute* C-24 stereochemistry in **5a** and **5b** as 24*S* and 24*R*, respectively. Similarly, pairwise comparison of  $^{13}\text{C}$  NMR signals of **6** with those of sitosterol<sup>10,14</sup> and its C-24 epimer clionasterol<sup>10,15</sup> allowed assignment of the 24*R* and 24*S* configurations to the epimers of phorbasterone D, **6a** and **6b**, respectively (note the change in CIP priorities at C24).

Phorbasterones A–D (**3**–**6**) showed moderate cytotoxicity ( $\text{IC}_{50}$  1–3  $\mu\text{g}/\text{mL}$ ) toward cultured HCT-116 colon tumor cells. The solvent fraction from which compounds **1**–**6** were derived was not active as a fish feeding deterrent in assays with *Thalassoma bifasciatum*.

In summary, we have identified four new ring A-contracted steroids, phorbasterones A–D (**3**–**6**), from *P. amaranthus*. Work on the chemical nature of the feeding deterrent principles is ongoing and will be reported in due course.

## Experimental Section

**Experimental Procedures.** General procedures are described elsewhere.<sup>16</sup> Mass spectrometric measurements were performed at University of California, Riverside Mass Spectrometry Facility. NMR measurements were carried out on a Varian Inova 400 MHz NMR spectrometer equipped with either a  $\{^1\text{H}\{^{15}\text{N}-^{31}\text{P}\}$  pulsed-field gradient (PFG) indirect-detection probe or  $^1\text{H}/^{13}\text{C}/^{15}\text{N}/^{31}\text{P}$  PFG auto-switchable probe. DQF-COSY experiments were carried out with gradient-enhanced pulse sequences.

**Animal Material.** *Phorbis amaranthus* (02-13-054) was collected by hand using scuba at -3 to -10 m at North Dry Rocks, Key Largo, FL (25°07.850' N, 080°17.521' W) and identified by one of the authors, J.R.P. The sponge was stored for 2 months at -20 °C before extraction. A voucher specimen stored at UNC Wilmington is available from J.R.P.

**Collection and Extraction of *P. amaranthus*.** The lyophilized tissue (339 g) was gently agitated in MeOH (800 mL) and  $\text{H}_2\text{O}$  (200 mL) using an overhead stirrer (5 °C for 24 h). After filtration, extraction of the tissue was repeated twice with fresh MeOH (900 mL) and  $\text{H}_2\text{O}$  (100 mL), and a third time with MeOH (100 mL) and  $\text{CHCl}_3$  (900 mL). Removal of volatiles from the  $\text{CHCl}_3$ -MeOH extract gave a deep-red gum (9.3 g). The majority of the extract (9.0 g) was applied to a silica column and eluted with a gradient (EtOAc in  $\text{CHCl}_3$ , then MeOH in  $\text{CHCl}_3$ ). The 20% EtOAc fraction contained the crude anthosterones **1** and **2** and phorbasterones **3**–**6**. This fraction was further separated on Sephadex LH-20 (1:3 hexane- $\text{CH}_2\text{Cl}_2$ ) to yield a purified fraction of **1**–**6** (90 mg). Final purification was achieved by reversed-phase HPLC ( $\text{C}_8$  Microsorb 90:10 MeOH- $\text{H}_2\text{O}$ , then  $\text{C}_{18}$ , Microsorb,  $\text{CH}_3\text{CN}-\text{H}_2\text{O}$ ) to afford, in order of elution, anthosterone A (**1**, 1.5 mg, 0.00037% dry wt), anthosterone B (**2**, 2.4 mg, 0.00059% dry wt), phorbasterone A (**3**, 4.4 mg, 0.0011% dry wt), phorbasterone

**Table 2.** Selected <sup>1</sup>H NMR Chemical Shifts of **2–6** (δ, CDCl<sub>3</sub>)<sup>a</sup>

#	<b>2</b>	<b>3</b>	<b>4</b>	<b>5<sup>d</sup></b>	<b>6</b>
1	2.10, d, <i>J</i> = 13.5 Hz 2.18, d, <i>J</i> = 13.5 Hz	2.08, d, <i>J</i> = 13.8 Hz 2.17, d, <i>J</i> = 13.8 Hz	2.09, d, <i>J</i> = 13.8 Hz 2.18, d, <i>J</i> = 13.8 Hz	2.08, d, <i>J</i> = 14 Hz 2.17, d, <i>J</i> = 14 Hz	2.08, d, <i>J</i> = 13.6 Hz 2.17, d, <i>J</i> = 13.6 Hz
6	6.73, t, <i>J</i> = 3.3 Hz	6.71, t, <i>J</i> = 3.6 Hz	6.73, t, <i>J</i> = 3.3 Hz	6.72, t, <i>J</i> = 3.6 Hz	6.72, t, <i>J</i> = 3.6 Hz
7	2.38, ddd, <i>J</i> = 4.0, 6.0, 21.0 <i>c</i>	2.38, ddd, <i>J</i> = 3.9, 6.0, 20.7 <i>c</i>	2.40, ddd, <i>J</i> = 3.9, 6.3, 20.7 <i>c</i>	2.37, ddd, <i>J</i> = 3.6, 5.7, 21.0 1.85, ddd, <i>J</i> = 3.6, 9.3, 21.0	2.38, ddd, <i>J</i> = 4.0, 6.0, 21.0 1.85, ddd, <i>J</i> = 4.0, 9.0, 21.0
18	0.73, s	0.72, s	0.72, s	0.72, s	0.71, s
19	1.20, s	1.20, s	1.20, s	1.20, s	1.18, s
21	0.96, d, <i>J</i> = 6.7 Hz	1.00, d, <i>J</i> = 6.6 Hz	0.93, d, <i>J</i> = 6.6 Hz	1.02, d, <i>J</i> = 6.4 Hz	0.91, d, <i>J</i> = 6.4 Hz
22	<i>c</i>	5.13–5.17, m	<i>c</i>	5.14, ddd, <i>J</i> = 2.8, 8.4, 15.2 Hz	<i>c</i>
23	<i>c</i>	5.13–5.17, m	<i>c</i>	5.01, ddd, <i>J</i> = 2.8, 8.4, 15.2 Hz	<i>c</i>
26 <sup>b</sup>	1.04, d, <i>J</i> = 6.5 Hz	0.89, d, <i>J</i> = 6.9 Hz	0.87, d, <i>J</i> = 6.6 Hz	0.83, d, <i>J</i> = 6.6 Hz	0.82, d, <i>J</i> = 6.6 Hz
27 <sup>b</sup>	1.04, d, <i>J</i> = 6.5 Hz	0.82, d, <i>J</i> = 6.9 Hz	0.86, d, <i>J</i> = 6.6 Hz	0.79, d, <i>J</i> = 6.6 Hz	0.79, d, <i>J</i> = 6.6 Hz
28		0.80, d, <i>J</i> = 6.6 Hz	-	<i>c</i>	<i>c</i>
OH	3.78, brd, <i>J</i> = 1.2 Hz	3.78, brd, <i>J</i> = 0.9 Hz	3.80, brs	3.78, brd, <i>J</i> = 0.9 Hz	3.78, brs
MeO	3.77, s	3.76, s	3.78	3.76	3.76

<sup>a</sup> Spectra of **2** and **6** were recorded at 400 MHz, while compounds **3**, **5**, and **6** were recorded at 300 MHz. <sup>b</sup> Chemical shifts for H26 and H27 are interchangeable. <sup>c</sup> Unresolved. <sup>d</sup> Assignments from DQFCOSY (600 MHz).

terone B (**4**, 6.7 mg, 0.0017% dry wt), phorbasterone C (**5**, 1.1 mg, 0.0003% dry wt), and phorbasterone D (**6**, 0.7 mg, 0.0002% dry wt).

(–)-**Phorbasterone A (3)**: colorless solid, [α]<sub>D</sub> –45.4° (*c* 0.19, CHCl<sub>3</sub>); UV (CH<sub>3</sub>CN) λ<sub>max</sub> 250 nm (ε 9600); IR (film) ν<sub>max</sub> 3453, 2956, 1745, 1720, 1651 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, see Table 2); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, see Table 1); HRMS (DEI) *m/z* 456.3247 [M<sup>+</sup>] (calcd for C<sub>29</sub>H<sub>44</sub>O<sub>4</sub>, 456.3239).

(–)-**Phorbasterone B (4)**: colorless solid, [α]<sub>D</sub> –54.6° (*c* 0.28, CHCl<sub>3</sub>); UV (CH<sub>3</sub>CN) λ<sub>max</sub> 250 nm (ε 9300); IR (film) ν<sub>max</sub> 3469, 2952, 1745, 1720, 1650 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, see Table 2); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, see Table 1); HRMS (DEI) *m/z* 444.3240 [M<sup>+</sup>] (calcd for C<sub>28</sub>H<sub>44</sub>O<sub>4</sub>, 444.3239).

**Phorbasterone C (5a and 5b)**: colorless solid, UV (CH<sub>3</sub>CN) λ<sub>max</sub> 250 nm (ε 9100); IR (film) ν<sub>max</sub> 3357, 2958, 1745, 1720, 1650, 1384 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, see Table 2); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, see Table 1); HRMS (DEI) *m/z* 470.3382 [M<sup>+</sup>] (calcd for C<sub>30</sub>H<sub>46</sub>O<sub>4</sub>, 470.3396).

**Phorbasterone D (6a and 6b)**: colorless solid, UV (CH<sub>3</sub>CN) λ<sub>max</sub> 250 nm (ε 9000); IR (film) ν<sub>max</sub> 3357, 2958, 1745, 1720, 1650 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, see Table 2); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, see Table 1); HRMS (DEI) *m/z* 472.3537 [M<sup>+</sup>] (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>4</sub>, 472.3552).

**Cytotoxicity Assays.** Cytotoxicity was measured with HCT-116 cells using the MTS method.<sup>17</sup> Briefly, compounds were assayed with compounds in DMSO (final concentration, 1% v/v) and run against etoposide as positive control. HCT-116 cells were incubated in 96-well plates for 72 h before addition of MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt)]. The Promega CellTiter 96 Aqueous cell proliferation assay (Technical Bulletin No. 169) was used. Well absorbances (λ 490 nm) were corrected for background and expressed as a percentage of the negative control (DMSO, only).

**Acknowledgment.** We thank J. Cowart (University of North Carolina, Wilmington) for assistance with collection of

*Phorbasp. sp.*, and S. Kelly (Scripps Institution of Oceanography) and S. Lievens (UCD) for performing the HCT-116 bioassays. The Bruker Avance 600 MHz spectrometer was purchased with funds provided by NIH RR11973. The Varian Inova 400 MHz spectrometer was purchased with funds provided by NSF CHE-9808183. This work was supported, in part, by grants from NIH (CA 85602) to T.F.M., and the NSF Biological Oceanography Program (OCE-0095724) and NOAA/National Undersea Research Center at UNCW to J.R.P.

## References and Notes

- Pawlik, J. R.; Chanas, B.; Toonen, R. J.; Fenical, W. *Mar. Ecol. Prog. Ser.* **1995**, *127*, 183–194.
- Chanas, B.; Pawlik, J. R. *Mar. Ecol. Prog. Ser.* **1995**, *127*, 195–211.
- Tischler, M.; Ayer, S. W.; Anderson, R. J.; Mitchell, J. F.; Clardy, J. *Can. J. Chem.* **1988**, *66*, 1173–1178.
- Rudi, A.; Stein, Z.; Green, S.; Goldberg, I.; Kashman, Y.; Benayahu, Y.; Schleyer, M. *Tetrahedron Lett.* **1994**, *35*, 2589–2592.
- Searle, P. A.; Molinski, T. F. *J. Am. Chem. Soc.* **1995**, *117*, 8126–8131.
- Searle, P. A.; Molinski, T. F.; Brzezinski, L. J.; Leahy, J. W. *J. Am. Chem. Soc.* **1996**, *118*, 9422–9423.
- McNally, M.; Capon, R. *J. Aust. J. Chem.* **2001**, *64*, 645–647.
- Rho, J.-R.; Lee, H.-S.; Sim, C. J.; Shin, J. *Tetrahedron* **2002**, *58*, 9585–9591.
- Findlay, J. A.; Patil, A. D. *Can. J. Chem.* **1985**, *63*, 2406–2410.
- Wright, J. L. C.; McInnes, A. G.; Shimizu, S.; Smith, D. G.; Walter, J. A.; Idler, D.; Khalil, W. *Can. J. Chem.* **1978**, *56*, 1898–1903.
- Blunt, J. W.; Stothers, J. B. *Org. Magn. Reson.* **1977**, *9*, 439–464.
- Holland, H. L.; Diakow, P. R. P.; Taylor, G. L. *Can. J. Chem.* **1978**, *56*, 3121–3127.
- Nicotra, F.; Ronchetti, F.; Russo, G.; Toma, L.; Ranzi, B. M. *Magn. Reson. Chem.* **1985**, *23*, 134–136.
- Nes, W. D.; Norton, R. A.; Benson, M. *Phytochemistry* **1992**, *31*, 805–811.
- Reynolds, W. F.; McLean, S.; Tay, L.-L.; Yu, M.; Enriquez, R. G.; Estwick, D. M.; Pascoe, K. O. *Magn. Reson. Chem.* **1997**, *35*, 455–462.
- Searle, P. A.; Richter, R. K.; Molinski, T. F. *J. Org. Chem.* **1996**, *61*, 4073–4079.
- Zhou, G.-X.; Molinski, T. F. *Mar. Drugs* **2003**, *1* (1), 46–53.

NP034037J